Key result
Treatment with R-EPOCH and dexrazoxane achieved complete remission in a patient with primary cardiac lymphoma.
Why the study?
Prognosis of primary cardiac lymphoma remains poor, and there is no treatment consensus because most information comes from case reports or series, with anthracycline-based chemotherapy presenting cardiotoxicity risks.
Comparison
R-EPOCH with dexrazoxane
Design
Case report
Authors
Loading...
Hypothesis-generating for R-EPOCH plus dexrazoxane in primary cardiac lymphoma; larger prospective studies needed before practice change.
Case Report (n=1)
R-EPOCH combined with dexrazoxane may be an effective treatment strategy for primary cardiac lymphoma, achieving complete remission while attempting to mitigate anthracycline-induced cardiotoxicity.
Anand et al. (2019) conducted a case report in Primary cardiac lymphoma (n=1). R-EPOCH and dexrazoxane was evaluated on Complete remission. Treatment with R-EPOCH and dexrazoxane achieved complete remission in a patient with primary cardiac lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: